The fund aims for long-term capital appreciation by investing in quality midcap companies with sustainable competitive advantages and significant growth potential
The rise came after the company announced that the United States Food and Drug Administration (US FDA) has approved its Sevelamer carbonate tablets 800 mg
The benchmark S&P BSE Sensex dropped by as much as 1,132 points to hit an intraday, while the Nifty 50 dropped to 21,932
The special live trading session will have intra-day switch over from primary site to disaster recovery site
Capital markets regulator Sebi has rejected a proposal by the National Stock Exchange (NSE) to extend the trading hours in the equity derivatives segment citing a lack of feedback from the stock brokers community. "Currently, there is no plan to extend the timings as Sebi has returned our application as the stock brokers have not given the feedback that Sebi wanted. So, as of now, the extended time frame (plan) is shelved," NSE MD and CEO Ashishkumar Chauhan said in a post-earnings analysts call. This came after the NSE had urged Sebi to extend trading hours in the equity derivatives segment in a phased manner. This was aimed at potentially curtailing the overnight risk arising from global information flow. Sriram Krishnan, Chief Business Development Officer of NSE, had told PTI in September that the bourse was planning a session from 6 pm to 9 pm after a break from the closure of the regular session from 9.15 am to 3.30 pm. Based on the response, a gradual extension of the market .
Arvind's topline grew 8.7 per cent year-on-year (Y-o-Y) to Rs 2,074.5 crore in Q4FY24, compared to Rs 1,880.7 crore in the corresponding period of the previous fiscal year
According to industry players, one of the key requirements for approving NSE's IPO is for it to remain free from any tech-glitch for a year
The company plans to utilise the net proceeds for working capital requirements and general corporate purposes
The NSE plans to launch options contracts based on key sectoral indices, including the pharmaceutical and IT indices, if it gets the regulatory go-ahead, according to two exchange sources
The grey market premiums (GMPs) for the three initial public offerings (IPOs) that open this week range between 20 per cent and 55 per cent
NSE also disclosed that it had filed a revised settlement plea with Sebi on March 5 in the trading access point (TAP) matter. It said it is awaiting a revert from Sebi on its plea
The NSE has been planning an initial public offering but needs approval from the Securities and Exchange Board of India (SEBI)
The 'continuation fund' will allow ChrysCapital to maintain its stake in the NSE, where it first invested in 2016, while the firm's older investors sell their stakes to new investors
Markets regulator Sebi has asked the National Stock Exchange (NSE) to designate a valuer to conduct the valuation of related party transactions between Linde India and Praxair India following complaints by shareholders. The matter relates to various transactions and agreements by Linde India Ltd (LIL) with its related parties Praxair India Pvt Ltd (PIPL) and Linde South Asia Services Pvt Ltd (LSASPL). Sebi investigated the case after receiving multiple complaints alleging that transactions and agreements entered by Linde India with Praxair India were in the nature of material related party transactions (RPTs) and Linde India did not obtain shareholders' approvals on these transactions. In its interim order passed on Monday, Sebi noted that Linde India was executing "related party transactions which prima facie appear to be material, without taking shareholder approval. Such actions effectively deprive public shareholders of an opportunity to express their views on transactions which
NSEIT is a leading provider of advanced digital transformation and cybersecurity services focused on global customers in capital markets, insurance, and banking
The surge in indices came on the back of a robust economy, optimistic forecasts from global brokerages and rating firms on economic growth outlook, and favourable investor sentiment
Poll expectations, easing of global tensions likely causes
National Stock Exchange (NSE) is set to introduce derivative contracts on Nifty Next 50 index from Wednesday. This came following an approval received from markets regulator Securities and Exchange Board of India (Sebi). The Nifty Next 50 index represents 50 companies from Nifty 100 after excluding the Nifty 50 companies. Under the derivative contract, the exchange would offer three serial monthly index futures and index options contract cycles. The cash-settled derivatives contracts would expire on the last Friday of the expiry month. The introduction of derivatives on the Nifty Next 50 index would complement the existing index derivatives product suite. The Nifty Next 50 index would represent the space between the Nifty 50 index comprising the top large & liquid stocks and the Nifty Midcap Select index comprising the top large & liquid mid-capitalised stocks, Sriram Krishnan, Chief Business Development Officer at NSE, stated last week. As of March 2024, the Nifty Next 50 ...
The National Stock Exchange (NSE) on Thursday said it will introduce derivative contracts on Nifty Next 50 index from April 24. The Nifty Next 50 index represents 50 companies from Nifty 100 after excluding the Nifty 50 companies. In a statement, NSE said it "has received approval for derivatives on Nifty Next 50 index from the Securities and Exchange Board of India (Sebi) and will launch these contracts from April 24, 2024". The exchange will offer three serial monthly index futures and index options contract cycles. The cash-settled derivatives contracts will expire on the last Friday of the expiry month. "The introduction of derivatives on the Nifty Next 50 index will complement the existing index derivatives product suite. The Nifty Next 50 index will represent the space between the Nifty 50 index comprising the top large & liquid stocks and the Nifty Midcap Select index comprising the top large & liquid mid-capitalised stocks," Sriram Krishnan, Chief Business Development .